At present, PD-1/PD-L1 inhibitors have been approved for the treatment of patients with advanced NSCLC, hepatocellular carcinoma, urothelial carcinoma, metastatic melanoma, and metastatic colorectal cancer [62]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.